Pulmonary Arterial Hypertension (PAH) Market
Pulmonary Arterial Hypertension (PAH) Market Analysis By Drug Class (Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), Phosphodiesterase-5 (PDE-5) Inhibitors, Soluble Guanylate Cyclase (sGC) Stimulators), By Pipeline Analysis (Early-stage Drug Candidates (Phase I & Phase II), Late-stage Drug Candidates (Phase III & Registration Phase)) and Region - Global Market Insights 2023 to 2033
Analysis of Pulmonary Arterial Hypertension (PAH) Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Pulmonary Arterial Hypertension (PAH) Market Overview (2023 to 2033)
The global pulmonary arterial hypertension market size was valued at US$ 5.4 Billion in 2023, and is projected to reach US$ 12.7 Billion by 2033, growing at a Compound Annual Growth Rate (CAGR) of 5.4% during the forecast period from 2023 to 2033.
Pulmonary arterial hypertension is a life-threatening medical disorder characterized by high blood pressure in the arteries that connect the heart and lungs. It causes the artery walls to constrict and thicken, increasing the pressure on the heart to pump blood and weakening the muscles.
Shortness of breath, tiredness, and swelling in the ankles and legs are all symptoms of PAH. Computed tomography (CT) scans, chest X-rays, ventilation-perfusion, and echocardiography studies are all used to diagnose it. Pulmonary arterial hypertension treatment providers are continually focusing on developing novel PAH diagnosis and PAH management solutions to improve patient care and maximize their business potential as well.
One of the primary factors driving the pulmonary arterial hypertension market growth is the rising frequency of cardiovascular diseases and arterial hypertension. Furthermore, the growing senior population, which is more prone to idiopathic pulmonary arterial hypertension (IPAH) and associated pulmonary arterial hypertension (APAH), is fuelling market expansion.
Excessive alcohol consumption, a lack of physical activity, and unhealthy dietary choices have all contributed to an increase in the risk of hypertension and high blood pressure. The aforementioned factors coupled with the development of novel drugs and advanced technologies for PAH treatments such as vasodilators and treprostinil are estimated to favor demand for pulmonary arterial hypertension treatment in the long run.
High demand for generic pulmonary arterial hypertension medications is anticipated to open up new frontiers of opportunities for established as well as new PAH drug providers.
- In April 2023, Dr. Reddy’s Laboratories, a leading pharmaceutical company based in India, announced the launch of its generic treprostinil injection in the United States. The product was made available in 20 mg/20 ml, 50 mg/20 ml, 100mg/20 ml, and 200 mg/20 ml vials for the treatment of pulmonary arterial hypertension.
Other factors, such as increased public awareness of the potential treatment options for heritable pulmonary arterial hypertension and improved healthcare infrastructure around the world, are likely to propel the pulmonary arterial hypertension market.
Contrastingly, the high cost of PAH drugs and therapies coupled with growing awareness regarding the side effects of PAH medications are expected to emerge as major constraints for global market growth in the long run.
PAH Market Size (2023)
US$ 5.4 Billion
Projected Market Value (2033F)
US$ 12.7 Billion
Global Market Growth Rate (2023 to 2033)
United States Market Share (2033)
Endothelin Receptor Antagonists (ERAs) Segment Share (2023)
Key Companies Profiled
Don't Need a Global Report?
save 40%! on Country & Region specific reports
What is the Prime Focus of New Companies in the Pulmonary Arterial Hypertension Business?
“Capital Raise Essential for New Pulmonary Arterial Hypertension Companies”
Aspiring pulmonary arterial hypertension treatment providers are projected to focus on raising new funding to finance their research and development efforts and improve their business scope on a global scale. Companies are slated to use the raised capital to fund product innovation and take their research programs to the next level.
- In October 2021, ShouTi Pharmaceuticals, a biotech company focusing on developing medicines using advanced computational technology, announced that it had raised US$ 100 million to develop small molecule drugs for different disorders. The company’s most advanced research program at the time was for a PAH drug that was in Phase 1 of development.
- In February 2020, Aria CV, a developer of cardiovascular devices which help treat pulmonary hypertension, announced that it had raised US$ 31 million in a Series B funding round led by Xeraya Capital and other investors. The funds were intended to be used for clinical trials of its lead product in the United States in hopes of commercialization of the same by 2033.
Through this elaborate pulmonary arterial hypertension research by skilled analysts at Fact.MR, a market research and competitive intelligence provider, start-ups can know more about trends such as local supply, pricing trends, product standards, safety regulations, and new developments that could alter the current or future competitive landscape.
What Restraints are Being Faced by PAH Drug Manufacturers?
“Side Effects Associated with PAH Drugs and High Cost of PAH Treatment”
Regulatory bodies around the world have been known to have lengthy drug approval processes to verify the drug's safety and efficacy. These lengthy procedures incur huge costs to drug development companies, which could hamper the overall pulmonary arterial hypertension market development across the study period.
Furthermore, the business of pulmonary arterial hypertension patient care companies is estimated to be restrained by leading companies terminating medications during clinical studies, patients' unawareness of the prevalence of pulmonary arterial hypertension, and high diagnosis and treatment costs.
Why are Pulmonary Arterial Hypertension Drug Suppliers Investing in India?
“Rapidly Rising Prevalence of Diabetes in the Country”
The PAH market in India is expected to grow at the fastest rate over the forecast period due to its huge population, quick economic development, and improved healthcare systems. In addition, rising initiatives for clinical research development are expected to fuel market growth.
Rise in the adoption of unhealthy diets and an increase in life expectancy are two major variables expected to boost diabetes cases in the country and drive the market. The rising prevalence of diabetes, increased generics consumption, the presence of major pharmaceutical companies, and easy access to high-quality pulmonary arterial hypertension treatments are all expected to drive the pulmonary arterial hypertension market.
Why is the United States Seen as an Opportune Market in This Space?
“Prominent Presence of Board-certified Physicians”
The United States is set to be a leading market and account for over 35% share of the global market by 2033.
Pulmonary arterial hypertension causes over 200,000 hospitalizations in the United States each year. The availability of board-certified physicians, rising hospital admissions linked to PAH, and the commercialization of new PAH medications, all of which are accompanied by a promising pharmacological pipeline, are driving market expansion in the United States.
Moreover, the United States PAH market is predicted to accelerate due to the rising prevalence of this illness due to heavy alcohol consumption, quick adoption of a sedentary lifestyle, and rising smoking habits among individuals.
Where in Europe Will Pulmonary Arterial Hypertension Treatment Demand Be High?
“United Kingdom to Lead European Market Expansion”
Surging prevalence of chronic diseases and expanding geriatric population are estimated to be the prime prospects promulgating sales of pulmonary arterial hypertension medications in the United Kingdom over the coming years. Growing pulmonary arterial hypertension awareness and rising availability of advanced PAH patient care solutions in the country are also estimated to boost pulmonary arterial hypertension market development through 2033.
The development of pulmonary arterial hypertension in people affected by HIV is a common probability and is slated to bolster demand for PAH diagnosis in the long run. New pulmonary arterial hypertension drug approvals and increasing awareness regarding the benefits of novel PAH therapies are projected to open up new avenues of opportunities for pulmonary arterial hypertension drug development companies going forward.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Which Drug Class is Likely to Accrue Maximum Gains?
“Therapeutic Advantages of Endothelin Receptor Antagonists Driving Their Popularity”
Endothelin receptor antagonists (ERAs) account for 45% share of the global PAH market at present.
Endothelin receptor antagonist drugs are widely suggested as a targeted therapy for reversing heart and lung damage, slowing PAH progression, and dilation of blood vessels, among other things. Clinical studies have shown that people with pulmonary arterial hypertension produce a lot of endothelin, which causes high blood pressure.
Physicians frequently prescribe endothelin receptor antagonists to lessen the amount of endothelin in the blood vessels. Furthermore, increasing investments in research and development efforts to offer new ERAs are expected to boost the PAH market growth.
Top-tier pulmonary arterial hypertension treatment providers are focusing on hastening the launch of new products by investing more in R&D, which is resulting in a higher number of PAH clinical trials being performed around the world.
- In January 2023, Liquidia Corporation, a pharmaceutical company based in the United States, announced that it had raised US$ 100 million by entering into a Revenue Interest Financing Agreement with HealthCare Royalty (HCRx). The company had plans of utilizing this capital to advance the R&D and manufacturing efforts for its pulmonary arterial hypertension treatment offerings.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Key Segments of Pulmonary Arterial Hypertension Industry Research
By Drug Class :
- Prostacyclin & Prostacyclin Analogs
- Endothelin Receptor Antagonists (ERAs)
- Phosphodiesterase-5 (PDE-5) Inhibitors
- Soluble Guanylate Cyclase (sGC) Stimulators
By Pipeline Analysis :
- Early-stage Drug Candidates (Phase I & Phase II)
- Late-stage Drug Candidates (Phase III & Registration Phase)
By Region :
- North America
- Latin America
- FAQs -
The global pulmonary arterial hypertension market is valued at US$ 5.4 billion in 2023.
The market for pulmonary arterial hypertension is predicted to reach US$ 12.7 billion by 2033.
From 2023 to 2033, the pulmonary arterial hypertension market is forecasted to rise at 5.4% CAGR.
Endothelin receptor antagonists (ERAs) currently account for 45% of the global PAH market share.
Pfizer Inc., GlaxoSmithKline Plc, Novartis International AG, Bayer HealthCare, and United Therapeutics Corp. are leading market players.